Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A. Reiss, Susan M. Domchek, Thomas B. Karasic et al.|Journal of Clinical Oncology|2021Cited by 238
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A. Reiss, Robert H. Vonderheide, Rosemarie Mick et al.|The Lancet Oncology|2022Cited by 137